{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:46:21Z","timestamp":1778647581764,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.07.014","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T21:07:48Z","timestamp":1692047268000},"page":"850-856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7278","authenticated-orcid":false,"given":"Eyal","family":"Lebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-5401","authenticated-orcid":false,"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Masih-Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8810","authenticated-orcid":false,"given":"Rodger","family":"Tiedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Kukreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2023.07.014_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.07.014_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.clml.2023.07.014_bib0003","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.07.014_bib0004","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2023.07.014_bib0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.07.014_bib0006","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V91.9.3148","article-title":"High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation","volume":"91","author":"Ketterer","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.07.014_bib0007","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705763","article-title":"Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies","volume":"40","author":"Bolwell","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.clml.2023.07.014_bib0008","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/blood-2009-11-252197","article-title":"Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission","volume":"116","author":"Gorin","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.07.014_bib0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.leu.2402796","article-title":"High numbers of mobilized stem cells in patients with acute myeloid leukemia in first complete remission: good or bad?","volume":"17","author":"De Witte","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2023.07.014_bib0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/bjc.2011.329","article-title":"High levels of circulating CD34+ cells at autologous stem cell collection are associated with favorable prognosis in multiple myeloma","volume":"105","author":"Raschle","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.07.014_bib0011","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.clml.2023.07.014_bib0012","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/bmt.2014.322","article-title":"Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation","volume":"50","author":"Brioli","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2023.07.014_bib0013","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12253-009-9238-x","article-title":"Correlation between survival and number of mobilized CD34+ cells in patients with multiple myeloma or Waldenstr\u00f6m macroglobulinemia","volume":"16","author":"Kakihana","year":"2010","journal-title":"Pathol Oncol Res"},{"issue":"10","key":"10.1016\/j.clml.2023.07.014_bib0014","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2023.07.014_bib0015","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.07.014_bib0016","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.07.014_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2307\/2532779","article-title":"Spline-based tests in survival analysis","volume":"50","author":"Gray","year":"1994","journal-title":"Biometrics"},{"issue":"10","key":"10.1016\/j.clml.2023.07.014_bib0018","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1080\/10428190701540991","article-title":"Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment","volume":"48","author":"Oakervee","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2023.07.014_bib0019","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.07.014_bib0020","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood.V112.11.3470.3470","article-title":"Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bortezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma (MM)","volume":"112","author":"Goldschmidt","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.07.014_bib0021","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/leu.2010.82","article-title":"Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial","volume":"24","author":"Moreau","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.07.014_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ejh.13404","article-title":"Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma","volume":"105","author":"Luttwak","year":"2020","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2023.07.014_bib0023","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bmt.2014.330","article-title":"Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective","volume":"50","author":"Saraceni","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.07.014_bib0024","first-page":"62","article-title":"Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34+CD38- cells as predictive tool for hematopoietic engraftment","volume":"15","author":"H\u00e9non","year":"2001","journal-title":"J Biol Regul Homeost Agents"},{"issue":"4","key":"10.1016\/j.clml.2023.07.014_bib0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.bmt.1700670","article-title":"Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation","volume":"19","author":"Gertz","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.clml.2023.07.014_bib0026","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3390\/cancers13164047","article-title":"Aberrant plasma cell contamination of peripheral blood stem cell autografts, assessed by next-generation flow cytometry, is a negative predictor for deep response post autologous transplantation in multiple myeloma: a prospective study in 199 patients","volume":"13","author":"Kostopoulos","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clml.2023.07.014_bib0027","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00432-004-0635-y","article-title":"Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation","volume":"131","author":"Vogel","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.07.014_bib0028","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clml.2023.07.014_bib0029","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.17316","article-title":"Poor mobilization of autologous CD34+ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential","volume":"193","author":"Gifford","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2023.07.014_bib0030","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1537-2995.2012.03848.x","article-title":"CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients","volume":"53","author":"Varmavuo","year":"2013","journal-title":"Transfusion"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:44:00Z","timestamp":1761871440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002331"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}